Skip to Main Content

Third Harmonic Bio has launched from stealth mode with $155 million to develop a single therapy that the Cambridge, Mass., startup hopes can treat multiple diseases caused by severe allergies and inflammation.

The experimental drug, which is in early clinical studies to test its safety, came from a set of molecules that the company licensed from pharmaceutical giant Novartis.


If the drug passes its safety trial, Third Harmonic plans to test it in people with cold-inducible urticaria, a condition where exposure to cold causes a person’s skin to break out in hives. That trial could begin this summer. If the drug works for those people, it could also help control flare-ups of hives in other forms of chronic urticaria.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.